ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Sandoz Group Ag

Sandoz Group Ag (0SAN)

0.00
0.00
(0.00%)
Closed 22 December 3:30AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
-
Bid
0.00
Offer
0.00
Volume
175,693
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
0.00
Open
-
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
9.65B
Net Profit
77M

About Sandoz Group Ag

Sector
Med, Dental, Hosp Eq-whsl
Industry
Med, Dental, Hosp Eq-whsl
Website
Headquarters
Rotkreuz, Che
Founded
-
Sandoz Group Ag is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker 0SAN. The last closing price for Sandoz was CHF0. Over the last year, Sandoz shares have traded in a share price range of CHF 0.00 to CHF 0.00.

Sandoz currently has 0 shares in issue.

0SAN Latest News

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation

Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz takes further steps...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal...

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz reports third-quarter and nine-month 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in...

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™...

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz reports second-quarter sales and half-year 2024 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of...

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches...

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar...

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe   Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...

Sandoz reports first quarter 2024 sales

Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5...

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG   All proposals of Board of Directors approvedGilbert Ghostine re-elected as...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

0SAN - Frequently Asked Questions (FAQ)

What is the current Sandoz share price?
The current share price of Sandoz is CHF 0.00
What is the 1 year trading range for Sandoz share price?
Sandoz has traded in the range of CHF 0.00 to CHF 0.00 during the past year
What is the reporting currency for Sandoz?
Sandoz reports financial results in USD
What is the latest annual turnover for Sandoz?
The latest annual turnover of Sandoz is USD 9.65B
What is the latest annual profit for Sandoz?
The latest annual profit of Sandoz is USD 77M
What is the registered address of Sandoz?
The registered address for Sandoz is SUURSTOFFI 14, ROTKREUZ, ROTKREUZ, 6343
What is the Sandoz website address?
The website address for Sandoz is www.sandoz.com
Which industry sector does Sandoz operate in?
Sandoz operates in the MED, DENTAL, HOSP EQ-WHSL sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TIRTiger Royalties And Investments Plc
0.15p
(50.00%)
3.41M
BAYBay Capital Plc
5.50p
(19.57%)
209.68k
MASTMast Energy Developments Plc
0.19p
(18.75%)
20.09M
MHNMenhaden Resource Efficiency Plc
148.50p
(18.33%)
1M
ZENZenith Energy Ltd.
2.50p
(16.28%)
3.93M
TRYBTribe Technology Plc
0.115p
(-79.09%)
24.27M
NMTNeometals Ltd
2.75p
(-35.29%)
49.4k
SNGSynairgen Plc
2.46p
(-34.31%)
4.31M
TM1Technology Minerals Plc
0.185p
(-26.00%)
174.03M
AYMAnglesey Mining Plc
0.70p
(-17.65%)
2.99M
NTVONativo Resources Plc
0.002p
(5.26%)
971.94M
TRPTower Resources Plc
0.035p
(9.38%)
620.03M
LLOYLloyds Banking Group Plc
54.16p
(-0.26%)
341.48M
ORCPOracle Power Plc
0.0255p
(-1.92%)
192.93M
TM1Technology Minerals Plc
0.185p
(-26.00%)
174.03M

Discussion

View Full Feed
Evergreen Plateau Evergreen Plateau 5 minutes ago
Ggsm name does not reflect business
Name change likely in the works
BIOCHEMUP BIOCHEMUP 6 minutes ago
Nice volume too
ONDS
train21 train21 6 minutes ago
didnt read that yet ??? looking ??
TONR
Golden Cross Golden Cross 6 minutes ago
Nice uptrend
ONDS
max mastiff max mastiff 7 minutes ago
MicroStrategy did a ten for one
HMBL
Evergreen Plateau Evergreen Plateau 7 minutes ago
Ggsm 9 month revenue so far 8.6 million
pos_stock_hoarder pos_stock_hoarder 7 minutes ago
We can't handle the truth!

They don't know what the truth even is!
eastunder eastunder 7 minutes ago
BB 3.69 +.71 (23%) on earnings

153 day cup/3.85 pivot/4.67 target

https://finviz.com/chart.ashx?t=bb&ty=c&ta=1&p=d&s=l
Evergreen Plateau Evergreen Plateau 8 minutes ago
Ggsm accumulate for massive gains
pos_stock_hoarder pos_stock_hoarder 10 minutes ago
Happy Saturday to you EZ. We had our first snow. What you'd call a big nothing burger!

Hope all is well.
dinogreeves dinogreeves 10 minutes ago
He is saying that, there was an article on Friday that Supermicro invested 20 million dollars in planting trees and vineyards, to help mitigate climate change and just maybe Charles likes drinking Wine. I believe LJ is trying to say there is no bullchit to that story, they have no reason to, it doe
SMCI
PennyStockTrader2 PennyStockTrader2 12 minutes ago
thanks. Im at around 500K shares, at these prices its worth it for me to maintain the position which is about 40% of my max. Its hard to predict what happens, but if we get another spike which is always possible, I will take most off the table as, like yourself, I have lost confidence in the company
DTGI
Investor082 Investor082 12 minutes ago
Doesn’t give anyone the reason to lie to shareholders. Lost over 60% value from that point on.

LP loves such bag holders!
NWBO
Evergreen Plateau Evergreen Plateau 13 minutes ago
Ggsm
Gonna load as much as possible at these levels
.ooo8 wow
Sideem Sideem 14 minutes ago
My break even price is $4.77. Just a buck and some change away.
BB
Evergreen Plateau Evergreen Plateau 14 minutes ago
Good day..
Not sure if you are still active..
Took a deep look at GGSM the other day..
Too much to list .
Check it out
Cheers
GGSM
GolfnutBoston GolfnutBoston 14 minutes ago
Rich, I'm not saying there's a company OneMind problem per se. 
FY2021 total revenue $935K
FY 2022 total revenue just under $1.5 million,
FY2023 on last years annual report stated just under $2 million in total revenue. 
So far this year 2024 from the 3 quarterly reports
AFFU
rouge Vaughn rouge Vaughn 15 minutes ago
nobody knows who you are I have made money here over 5 figures and will continue
go get dividend package you want a steady flow of income with little to no work. speak for yourself you do not speak for me or anyone else we will continue to make money here and load up while it's cheap as for
NSAV
JRoon71 JRoon71 15 minutes ago
Denisk, I got the impression that it was 180EU to Amarin, and the difference (to 239) is the allowable markup that pharmacies are allowed for their own costs and profit.

Maybe I am reading it wrong.
AMRN
manibiotech manibiotech 15 minutes ago
Well they didn't specify revenue to whom
NWBO
PennyStockTrader2 PennyStockTrader2 15 minutes ago
to your points ...

1) maybe maybe not, thats to be determined. A better way to look at it is to make sure you own lots of those cheap shares.
2) the notes come due every so often its just one lender thats it, they get a price and they get shares, and its a lot of shares as we'v
IPSI

Your Recent History

Delayed Upgrade Clock